General public

You are here

FIRE CORAL: Functional, Imaging, and Respiratory Evaluation in CORAL

June 2021 to February 2022


FIRE CORAL is an ancillary study to BLUE CORAL that aims to describe post-hospital outcomes for patients previously hospitalized with COVID-19. This study looks at lung function, recovery trajectories, and biospecimens to better understand clinical and biologic factors associated with persistent impairment of the lungs.

Who can be in this study?

Adults who were enrolled in BLUE CORAL and participated in the 1-month post-hospitalization telephone assessment may be eligible for this study. Only hospitals that are part of the PETAL Network and participating in FIRE CORAL can enroll subjects.

What happens in this study?

  • Participants will take part in a variety of assessments. These include , questionnaires, breathing tests, walking and strength tests , a chest CT scan andblood collection.
  • Some participants may be asked to return for a second visit 3 months after the first to track their recovery.

Who is paying for this study?

The National Heart, Lung and Blood Institute (NHLBI), which is part of the U.S. government, is paying for this research.

Trial Summary:


FIRE CORAL is an ancillary study to BLUE CORAL enrolling a subset of patients for long-term follow-up. This study aims to collect objective in-person clinical assessments of patients after hospital discharge in order to describe recovery after COVID-19. The PETAL network aims to address key information gaps and contribute foundational knowledge to the epidemiology and biology of COVID-19.

Study Design:

Observational study

Primary Objectives

Describe the clinical characteristics, treatments, biology, and outcomes of hospitalized patients with COVID-19

Secondary Objectives

  • To describe the prevalence of abnormalities of pulmonary function, chest imaging, and functional status in patients hospitalized with COVID-19 3 months after discharge
  • To determine trajectory of recovery of pulmonary function and functional status between 3 and 6 months after COVID-19
  • To identify clinical and biologic factors associated with persistent impairment of pulmonary function, chest imagine, and functional status after hospitalization with COVID-19
  • To determine the independent association between patient-reported outcomes of impaired recovery with objective measures of pulmonary function and persistent inflammation
  • To create a repository of biospecimens that permits longitudinal analysis of biomarkers spanning hospitalization to posthospital discharge

Study Size:

This study will enroll approximately 80 people previously hospitalized due to COVID-19 infection.